KEYTRUDA (PEMBROLIZUMAB) Wholesaler

Keytruda (Pembrolizumab) , wholesaler

KEYTRUDA (PEMBROLIZUMAB) DESCRIPTION:

Keytruda  is a humanized antibody used in cancer immunotherapy. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells and thereby allows the immune system to destroy them

KEYTRUDA (PEMBROLIZUMAB) INDICATIONS:

• Treatment of recurrent or metastatic cervical cancer in patients whose tumors express PD-L1 (combined positive score [CPS] ≥ 1), as determined by an approved test, and with disease progression on or after chemotherapy.
• Treatment of recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy, and if appropriate, HER2/neu-targeted therapy.
• For the treatment of unresectable or metastatic melanoma.
• For the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection
• Patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy.
• For treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.
• Treatment of primary mediastinal large B-cell lymphoma (PMBCL) in adult or pediatric patients with refractory disease ow ho have relapsed after 2 or more prior lines of therapy.
• For treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy.
• For treatment of locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.
• For treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors or colorectal cancer that have progressed following prior treatment.
• For treatment of patients with hepatocellular cancer (HCC) who have been previously treatment with sorafenib.
• For Treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell cancer.

DOSAGE FORM & STRENGTH:

• Keytruda 50mg/vial Wholesaler
• Keytruda 200mg/4mL (25mg/mL) Supplier

Rasso Swiss Pharma is a Keytruda distributor, supplier and wholesaler.

<< Back to products